Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A somatic mutation of the KEAP1 gene in malignant melanoma is involved in aberrant NRF2 activation and an increase in intrinsic drug resistance.

Literature DB >> 23938463

A somatic mutation of the KEAP1 gene in malignant melanoma is involved in aberrant NRF2 activation and an increase in intrinsic drug resistance.

Shinpei Miura¹, Masahiko Shibazaki², Shuya Kasai³, Shinji Yasuhira³, Ayano Watanabe¹, Tsuyoshi Inoue¹, Yuich Kageshita¹, Kanako Tsunoda⁴, Kazuhiro Takahashi⁴, Toshihide Akasaka⁴, Tomoyuki Masuda⁵, Chihaya Maesawa³.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2013 PMID： 23938463 DOI： 10.1038/jid.2013.343

Source DB: PubMed Journal: J Invest Dermatol ISSN： 0022-202X Impact factor: 8.551

× No keyword cloud information.

14 in total

1. Nrf2 degradation by the ubiquitin proteasome pathway is inhibited by KIAA0132, the human homolog to INrf2.

Authors: Konjet R Sekhar; Xue Xian Yan; Michael L Freeman
Journal: Oncogene Date: 2002-10-03 Impact factor: 9.867

2. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.

Authors: Gerald Saldanha; Linda Potter; Philip Daforno; J Howard Pringle
Journal: Clin Cancer Res Date: 2006-08-01 Impact factor: 12.531

3. Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway.

Authors: Victor Huang; Donna Hepper; Milan Anadkat; Lynn Cornelius
Journal: Arch Dermatol Date: 2012-05

4. Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas.

Authors: Kevin G Chen; Julio C Valencia; Barry Lai; Guofeng Zhang; Jill K Paterson; François Rouzaud; Werner Berens; Stephen M Wincovitch; Susan H Garfield; Richard D Leapman; Vincent J Hearing; Michael M Gottesman
Journal: Proc Natl Acad Sci U S A Date: 2006-06-15 Impact factor: 11.205

Review 5. Molecular mechanisms of the Keap1–Nrf2 pathway in stress response and cancer evolution.

Authors: Keiko Taguchi; Hozumi Motohashi; Masayuki Yamamoto
Journal: Genes Cells Date: 2011-02 Impact factor: 1.891

Review 6. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets.

Authors: D Grossman; D C Altieri
Journal: Cancer Metastasis Rev Date: 2001 Impact factor: 9.264

7. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.

Authors: Eric W Joseph; Christine A Pratilas; Poulikos I Poulikakos; Madhavi Tadi; Weiqing Wang; Barry S Taylor; Ensar Halilovic; Yogindra Persaud; Feng Xing; Agnes Viale; James Tsai; Paul B Chapman; Gideon Bollag; David B Solit; Neal Rosen
Journal: Proc Natl Acad Sci U S A Date: 2010-07-28 Impact factor: 11.205

8. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.

Authors: James Tsai; John T Lee; Weiru Wang; Jiazhong Zhang; Hanna Cho; Shumeye Mamo; Ryan Bremer; Sam Gillette; Jun Kong; Nikolas K Haass; Katrin Sproesser; Ling Li; Keiran S M Smalley; Daniel Fong; Yong-Liang Zhu; Adhirai Marimuthu; Hoa Nguyen; Billy Lam; Jennifer Liu; Ivana Cheung; Julie Rice; Yoshihisa Suzuki; Catherine Luu; Calvin Settachatgul; Rafe Shellooe; John Cantwell; Sung-Hou Kim; Joseph Schlessinger; Kam Y J Zhang; Brian L West; Ben Powell; Gaston Habets; Chao Zhang; Prabha N Ibrahim; Peter Hirth; Dean R Artis; Meenhard Herlyn; Gideon Bollag
Journal: Proc Natl Acad Sci U S A Date: 2008-02-19 Impact factor: 11.205

9. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer.

Authors: Tatsuhiro Shibata; Akiko Kokubu; Masahiro Gotoh; Hidenori Ojima; Tsutomu Ohta; Masayuki Yamamoto; Setsuo Hirohashi
Journal: Gastroenterology Date: 2008-07-03 Impact factor: 22.682

10. Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005.

Authors: Porcia T Bradford; Alisa M Goldstein; Mary L McMaster; Margaret A Tucker
Journal: Arch Dermatol Date: 2009-04

14 in total

1. Heme oxygenase promotes B-Raf-dependent melanosphere formation.

Authors: Kimberly J Jasmer; Jie Hou; Philip Mannino; Jianlin Cheng; Mark Hannink
Journal: Pigment Cell Melanoma Res Date: 2020-07-09 Impact factor: 4.693

2. Carnosic acid, an inducer of NAD(P)H quinone oxidoreductase 1, enhances the cytotoxicity of β-lapachone in melanoma cell lines.

Authors: Nobuyuki Arakawa; Ayaka Okubo; Shinji Yasuhira; Kazuhiro Takahashi; Hiroo Amano; Toshihide Akasaka; Tomoyuki Masuda; Masahiko Shibazaki; Chihaya Maesawa
Journal: Oncol Lett Date: 2017-12-14 Impact factor: 2.967

3. Sestrin2 protein positively regulates AKT enzyme signaling and survival in human squamous cell carcinoma and melanoma cells.

Authors: Baozhong Zhao; Palak Shah; Andrei V Budanov; Lei Qiang; Mei Ming; Andrew Aplin; Diane M Sims; Yu-Ying He
Journal: J Biol Chem Date: 2014-11-06 Impact factor: 5.157

A somatic mutation of the KEAP1 gene in malignant melanoma is involved in aberrant NRF2 activation and an increase in intrinsic drug resistance.

1. Nrf2 degradation by the ubiquitin proteasome pathway is inhibited by KIAA0132, the human homolog to INrf2.

2. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.

3. Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway.

4. Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas.

Review 5. Molecular mechanisms of the Keap1–Nrf2 pathway in stress response and cancer evolution.

Review 6. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets.

7. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.

8. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.

9. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer.

10. Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005.

1. Heme oxygenase promotes B-Raf-dependent melanosphere formation.

2. Carnosic acid, an inducer of NAD(P)H quinone oxidoreductase 1, enhances the cytotoxicity of β-lapachone in melanoma cell lines.

3. Sestrin2 protein positively regulates AKT enzyme signaling and survival in human squamous cell carcinoma and melanoma cells.

Review 4. p62 links autophagy and Nrf2 signaling.

Review 5. Anticancer Activity of Sulforaphane: The Epigenetic Mechanisms and the Nrf2 Signaling Pathway.

Review 6. Non-Apoptotic Cell Death Signaling Pathways in Melanoma.

7. Nuclear Factor Erythroid 2-Related Factor 2 in Regulating Cancer Metabolism.

Review 8. The clinical potential of influencing Nrf2 signaling in degenerative and immunological disorders.

9. NAD(P)H:Quinone Oxidoreductase-1 Expression Sensitizes Malignant Melanoma Cells to the HSP90 Inhibitor 17-AAG.

10. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.